Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (186)	10/16/2002 1:34:30 AM
From: tuck	Read Replies (1) \| Respond to of 447

>>Nonetheless, market is acting like this are FACTS (for ABGX and OSIP).<< Indeed. Uncertainty and toppy short term market are a tough combo for the anti-EGF players now. I think OSIP and ABGX could easily test their lows in a few days because of this combination, and that will be the time for a trade on the long side. I would go with ABGX in the middle $5s, personally. Edit: the range on ABGX today was quite striking, whereas OSIP was simply down. As if the Street was trying to decide if small molecule inhibitors of EGF were in trouble, but antibodies might be OK. By the end of the day, the action seemed to say it thinks EGF inhibition as a whole is in trouble. Makes me wonder if the big boys phoned their doctor consultants and were told that. Cheers, Tuck